Drug Trial Radar · NCT03120949
Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Oct 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,106
Actual
Start
Jul 4, 2017
Primary completion
Sep 1, 2021
Study completion Sep 1, 2021
Sponsor
- Lead sponsor
- R-Pharm International, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Pvt. Ltd; OCT Clinical Trials
- First posted
- Apr 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects with moderately to severely active rheumatoid arthritis (RA) who previously had completed 24 weeks of double-blind treatment in Study CREDO 1, 2 or 3 (core studies). The long-term efficacy, immunogenicity, the physical function and quality of life of subjects received long-term treatment with OKZ were assessed as well.
Conditions
- Rheumatoid Arthritis
Interventions
Olokizumab 64 mg SC q4wDrug
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
Olokizumab 64 mg SC q2wDrug
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
Concomitant treatmentDrug
Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.) Folic acid ≥ 5 mg per week or equivalent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population)Time frame: up to Week 126
- Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population)Time frame: up to Week 126
- Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI)Time frame: up to Week 126
- Incidence of Treatment-Emergent AEs Leading to Withdrawal of the Study TreatmentTime frame: up to Week 126
- Incidence Rate of Treatment Emergent AEs Per Patient-years of ExposureTime frame: up to Week 126
- Incidence Rate of Treatment Emergent SAEs Per Patient-years of ExposureTime frame: up to Week 126
- Incidence Rate of Treatment Emergent AESIs (Safety Population)Time frame: up to Week 126
Locations
239 sites in 18 countries. Site status is shown where the registry gives one.
AZ Arthritis & Rheum' Research
Mesa, Arizona
Arizona Arthritis & Rheumatology Associates, P.C.
Phoenix, Arizona
Arizona Arthritis & Rheumatology Research, PLLC
Sun City, Arizona
CHI St. Vincent Hot Springs
Hot Springs, Arkansas
Medvin Clinical Research
Covina, California
C.V Mehta MD Med Corp..
Hemet, California
Advanced Medical Research, LLC
La Palma, California
Valerius Medical Group
Los Alamitos, California
Stanford University School of Medicine
Palo Alto, California
Rheumatology Center of San Diego
San Diego, California
East Bay Rheumatology Medical Group, Inc.
San Leandro, California
Inland Rheumatology Clinical Trials, Inc.
Upland, California
Center for Rheumatology Research, Comprehensive Rheumatology Center
West Hills, California
Medvin Clinical Research
Whittier, California
Denver Arthritis Clinic
Denver, Colorado
New England Research Associates LLC
Bridgeport, Connecticut
Javed Rheumatology Associates
Newark, Delaware
RASF - Clinical Research Center
Boca Raton, Florida
Reliable Clinical Research, LLC
Hialeah, Florida
Pharmax Research Clinic
Miami, Florida
Medical Research Center of Miami
Miami, Florida
Suncoast Research Group, LLC
Miami, Florida
Omega Research Consultants
Orlando, Florida
Arthritis Research of Florida, INC
Palm Harbor, Florida
Family Clinical Trials, LLC.
Pembroke Pines, Florida
AdventHealth Medical Group, PA
Tampa, Florida
Lovelace Scientific Resources, Inc.
Venice, Florida
Arthritis Center of North Georgia
Gainesville, Georgia
Marietta Rheumatology Associates, PC
Marietta, Georgia
Institute of Arthritis Research
Idaho Falls, Idaho
University of Kansas Hospital
Kansas City, Kansas
Graves Gilbert Clinic
Bowling Green, Kentucky
The Arthritis & Diabetes Clinic, Inc.
Monroe, Louisiana
Klein and Associates, M.D., P.A.
Hagerstown, Maryland
The Center for Rheumatology and Bone Research
Wheaton, Maryland
Clinical Pharmacology Study Group
Worcester, Massachusetts
AA MRC LLC Ahmed Arif Medical Research Center
Grand Blanc, Michigan
North MS Medical Clinics, Inc.
Tupelo, Mississippi
Glacier View Research Institute-Rheumatology
Kalispell, Montana
Physician Research Collaboration
Lincoln, Nebraska
Showing 40 of 239 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.